Knowledge graph · Trial
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
ACTIVE NOT RECRUITING
- Identifier
- CI-TRIAL-00122077
- Entity page
- /trial/NCT05259839 ↗
- Edges
- 5
- Neighbours
- 1 cancers4 drugs
- Drawn
- 5 of 5 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,149Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma condition of …CONDITION_OFderived1 of 1 | ||||||||
| ← condition of | Multiple Myeloma registry condition “Relapsed/Refractory Multiple Myeloma” mapped CURATED_EXACT | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma … | ||||||||